Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chubb
Julphar
Deloitte
Argus Health
Merck
Citi
Colorcon
Harvard Business School

Generated: February 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BICALUTAMIDE

« Back to Dashboard

Clinical Trials for Bicalutamide

Trial ID Title Status Sponsor Phase Summary
NCT00002633 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed Eastern Cooperative Oncology Group Phase 3 RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether hormone therapy plus surgery is more effective than hormone therapy plus radiation therapy for prostate cancer. PURPOSE: This randomized phase III trial is studying giving hormone therapy alone to see how well it works compared to giving hormone therapy together with bilateral orchiectomy or radiation therapy in treating patients with stage III or stage IV prostate cancer.
NCT00002633 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed Medical Research Council Phase 3 RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether hormone therapy plus surgery is more effective than hormone therapy plus radiation therapy for prostate cancer. PURPOSE: This randomized phase III trial is studying giving hormone therapy alone to see how well it works compared to giving hormone therapy together with bilateral orchiectomy or radiation therapy in treating patients with stage III or stage IV prostate cancer.
NCT00002633 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed National Cancer Institute (NCI) Phase 3 RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether hormone therapy plus surgery is more effective than hormone therapy plus radiation therapy for prostate cancer. PURPOSE: This randomized phase III trial is studying giving hormone therapy alone to see how well it works compared to giving hormone therapy together with bilateral orchiectomy or radiation therapy in treating patients with stage III or stage IV prostate cancer.
NCT00002633 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed Southwest Oncology Group Phase 3 RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether hormone therapy plus surgery is more effective than hormone therapy plus radiation therapy for prostate cancer. PURPOSE: This randomized phase III trial is studying giving hormone therapy alone to see how well it works compared to giving hormone therapy together with bilateral orchiectomy or radiation therapy in treating patients with stage III or stage IV prostate cancer.
NCT00002633 Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer Completed NCIC Clinical Trials Group Phase 3 RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether hormone therapy plus surgery is more effective than hormone therapy plus radiation therapy for prostate cancer. PURPOSE: This randomized phase III trial is studying giving hormone therapy alone to see how well it works compared to giving hormone therapy together with bilateral orchiectomy or radiation therapy in treating patients with stage III or stage IV prostate cancer.
NCT00002651 Hormone Therapy in Treating Men With Stage IV Prostate Cancer Unknown status Cancer and Leukemia Group B Phase 3 RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer. It is not yet known which regimen of hormone therapy is most effective for stage IV prostate cancer. PURPOSE: This randomized phase III trial is studying two different regimens of hormone therapy and comparing how well they work in treating men with stage IV prostate cancer.
NCT00002651 Hormone Therapy in Treating Men With Stage IV Prostate Cancer Unknown status Eastern Cooperative Oncology Group Phase 3 RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer. It is not yet known which regimen of hormone therapy is most effective for stage IV prostate cancer. PURPOSE: This randomized phase III trial is studying two different regimens of hormone therapy and comparing how well they work in treating men with stage IV prostate cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Bicalutamide

Condition Name

Condition Name for Bicalutamide
Intervention Trials
Prostate Cancer 85
Adenocarcinoma of the Prostate 10
Stage IV Prostate Cancer 7
Prostatic Neoplasms 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bicalutamide
Intervention Trials
Prostatic Neoplasms 114
Adenocarcinoma 14
Breast Neoplasms 8
Triple Negative Breast Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bicalutamide

Trials by Country

Trials by Country for Bicalutamide
Location Trials
United States 783
Canada 98
Japan 26
United Kingdom 26
Italy 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bicalutamide
Location Trials
New York 29
Texas 28
California 28
Maryland 27
Michigan 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bicalutamide

Clinical Trial Phase

Clinical Trial Phase for Bicalutamide
Clinical Trial Phase Trials
Phase 4 5
Phase 3 37
Phase 2/Phase 3 1
[disabled in preview] 88
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bicalutamide
Clinical Trial Phase Trials
Completed 57
Active, not recruiting 23
Recruiting 21
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bicalutamide

Sponsor Name

Sponsor Name for Bicalutamide
Sponsor Trials
National Cancer Institute (NCI) 45
AstraZeneca 14
Radiation Therapy Oncology Group 10
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bicalutamide
Sponsor Trials
Other 143
Industry 65
NIH 45
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Fuji
Teva
Accenture
Deloitte
Harvard Business School
US Army
Medtronic
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.